Bayer’s Supplement Sales Leap By A Third On COVID Boost

Bayer posts double-digit rise in Q1 Consumer Health sales off the back of unprecedented demand for its dietary supplements in the middle of the global coronavrius pandemic. 

BayerSign
• Source: Shutterstock

Increased demand globally for immunity boosting products against the backdrop of the COVID-19 pandemic saw sales at Bayer Consumer Health’s Nutritionals category leap ahead by a third in the first quarter.

Sales of Nutritionals – which Bayer defines as multivitamins and dietary supplements – advanced by 32% to €351m ($382m) in the opening three months of 2020 as turnover from the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By 

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”

More from Business

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.